Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prognosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    367 result(s) found for: Prognosis. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-001270-33 Sponsor Protocol Number: GCTSK003 Start Date*: 2015-07-28
    Sponsor Name:Národný onkologický ústav
    Full Title: A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel...
    Medical condition: Disseminated Non-Seminomatous Germ Cell Tumors.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000971-17 Sponsor Protocol Number: 58335 Start Date*: 2019-07-17
    Sponsor Name:UZ Brussel
    Full Title: Double trigger and ovum retrieval vs. conventional antagonist ovarian stimulation protocol in poor prognosis women undergoing IVF/ICSI: A pilot study
    Medical condition: infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005398-30 Sponsor Protocol Number: dopa Start Date*: 2013-05-03
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA
    Full Title: Diagnostic efficacy and prognostic method [18F] DOPA-PET/CT in study of neuroblastoma: comparison with 123I-MIBG scintigraphy
    Medical condition: patients wiht NB onset with high probability to return in stages 3 and 4 of the disease on the basis of the ultrasound images or TC. May also be included with the two-stage amplification of N-MYC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-005043-97 Sponsor Protocol Number: 04/MA/003E Start Date*: 2005-06-30
    Sponsor Name:St Mary's NHS Trust
    Full Title: A Pilot study investigating the use of Intravitreal Triamcinolone prior to macular laser for Clinically Significant Diabetic Macular Oedema
    Medical condition: Macular oedema affects 29% of diabetic patients and is the main cause of visual impairment. Previous studies show that diffuse macular oedema carries a particularly poor prognosis despite laser pho...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001804-31 Sponsor Protocol Number: CSTI571AJP02 Start Date*: 2017-08-10
    Sponsor Name:Novartis Pharma K.K
    Full Title: Ph3 trial of Glivec in CML-CP patients previously untreated with IFN-alfa
    Medical condition: CML-CP patients
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002948-14 Sponsor Protocol Number: SC-FET15 Start Date*: 2015-09-22
    Sponsor Name:PET Diagnosztikai Kft.
    Full Title: Application of a new radioligand F-18 FET, and its clinical benefit in the diagnosis of primary and secondary brain tumors
    Medical condition: Primary and secondary brain tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-000637-12 Sponsor Protocol Number: P170909J Start Date*: 2019-03-29
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitis
    Medical condition: Patients with newly diagnosed or relapsing MPA, without any poor prognosis marker (FFS=0). Stratification will be made according to peripheral nerve involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001072-13 Sponsor Protocol Number: GETUG13 Start Date*: 2005-10-25
    Sponsor Name:UNICANCER
    Full Title: A risk-adapted strategy of the use of dose-dense chemotherapy in patient with poor-prognosis dissemined non-seminomatous germ cell tumors. GETUG 13 / 0206
    Medical condition: Non-Seminoma Germ Cell Tumor
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: SK (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006638-38 Sponsor Protocol Number: 2021/3282 Start Date*: Information not available in EudraCT
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06)
    Medical condition: Non-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004817-15 Sponsor Protocol Number: CTOO19099GZA Start Date*: 2020-03-12
    Sponsor Name:GZA vzw
    Full Title: A prospective, biomarker-based, clinical trial in patients with metastatic castration resistant prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002610-37 Sponsor Protocol Number: SIREPNA/05 Start Date*: 2005-12-05
    Sponsor Name:NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE)
    Full Title: PILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS. Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas d...
    Medical condition: To test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003123-22 Sponsor Protocol Number: JCS-CBG-2014-01 Start Date*: 2015-01-02
    Sponsor Name:José Castillo Sanchez
    Full Title: "Randomized clinical trial with two parallel groups, double-blind, placebo-controlled trial to investigate whether administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemi...
    Medical condition: Acute ischemic stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002645-38 Sponsor Protocol Number: BIOMARCHA Start Date*: 2012-09-04
    Sponsor Name:CRESIB-Barcelona Centre for International Health Research
    Full Title: Evolution of serologic biomarkers and diastolic function and segmentary contractility determined by echocardiography after treatment in Chagas diseases
    Medical condition: The study will be held in 63 patients with chronic Chagas Disease and 63 healthy people
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004082-39 Sponsor Protocol Number: GOOD-IDES-01 Start Date*: 2017-01-23
    Sponsor Name:Linköping University
    Full Title: An Open-Label Phase II Study in anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES
    Medical condition: Anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10063039 Anti-GBM antibody LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-006962-41 Sponsor Protocol Number: CSTI571ADE60 Start Date*: 2008-03-27
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia
    Medical condition: Chronic myeloid leukemia is a malignant disease of the blood. Without therapy it has an unfavourable prognosis. Under first-line therapy with newer inhibitors of the thymidinkinase some few patien...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003399-58 Sponsor Protocol Number: COPTRIN1 Start Date*: 2017-01-14
    Sponsor Name:COP:TRIN Region Hovedstaden (Gentofte hospital)
    Full Title: Target-ABC (Targeted AntiBiotics for Chronic pulmonary disease): Can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa infected patients with chronic pulmonary obstructiv...
    Medical condition: Respiratory tract infection Bacterial infection with Pseudomonas aeruginosa Chronic obstructive pulmonary disease (COPD) Non-cystic fibrosis bronchiectasis Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021860 Infection Pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002098-25 Sponsor Protocol Number: ZKSJ0137_INFLIXCOVID Start Date*: 2021-05-27
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: A randomized, controlled, multicenter, open label phase II clinical study to evaluate infliximab in the treatment of patients with severe COVID-19 disease (INFLIXCOVID)
    Medical condition: severe COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001336-10 Sponsor Protocol Number: AGNES-19 Start Date*: 2022-03-25
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Multicenter, randomized, double-blind, biomarker-guided, phase II trial with Adrecizumab (HAM 8101) to improve proGNosis and outcomES in patients with moderate to severe covid-19 - Adrecizumab (HAM...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009882-33 Sponsor Protocol Number: TE-2009-01 Start Date*: 2010-06-10
    Sponsor Name:St Bartholomew's and The London NHS Trust
    Full Title: A multi-centre phase II study using Carboplatin AUC-10 for metastatic seminoma with IGCCCG good prognosis disease - therapy directed by initial metabolic response on PET-CT [CAR-PET]
    Medical condition: Metastatic seminoma
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005295-27 Sponsor Protocol Number: TE 2008 01 Start Date*: 2009-05-14
    Sponsor Name:Barts and The London NHS Trust
    Full Title: A NOVEL HYBRID PROTOCOL FOR RELAPSED GERM CELL TUMOURS WITH POOR PROGNOSIS
    Medical condition: Relapsed Germ Cell Tumour with poor prognosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 27 17:25:15 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA